Literature DB >> 33849635

Vaccine market and production capabilities in the Americas.

Esteban Ortiz-Prado1,2, Estefanía Espín3, Jorge Vásconez3, Nathalia Rodríguez-Burneo3, Nikolaos C Kyriakidis3, Andrés López-Cortés4,5.   

Abstract

In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals' distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology.Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic.Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans.

Entities:  

Keywords:  Economic dependence; Latin America; Market; Vaccine coverages; Vaccines

Year:  2021        PMID: 33849635     DOI: 10.1186/s40794-021-00135-5

Source DB:  PubMed          Journal:  Trop Dis Travel Med Vaccines        ISSN: 2055-0936


  12 in total

Review 1.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

2.  Elimination of rubella and congenital rubella syndrome in the Americas.

Authors:  Carlos Castillo-Solórzano; Christina Marsigli; Pamela Bravo-Alcántara; Brendan Flannery; Cuauhtémoc Ruiz Matus; Gina Tambini; Socorro Gross-Galiano; Jon Kim Andrus
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

Review 3.  WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.

Authors:  Martin Friede; Laszlo Palkonyay; Claudia Alfonso; Yuri Pervikov; Guido Torelli; David Wood; Marie Paule Kieny
Journal:  Vaccine       Date:  2011-07-01       Impact factor: 3.641

Review 4.  Coagulation factors and their inhibitors.

Authors:  M T Stubbs; W Bode
Journal:  Curr Opin Struct Biol       Date:  1994-12       Impact factor: 6.809

Review 5.  Argentine hemorrhagic fever vaccines.

Authors:  Ana Ambrosio; Maria Saavedra; Mauricio Mariani; Graciela Gamboa; Andrea Maiza
Journal:  Hum Vaccin       Date:  2011-06-01

6.  Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.

Authors:  Jaime L Rubin; Lisa J McGarry; David R Strutton; Keith P Klugman; Stephen I Pelton; Kristen E Gilmore; Milton C Weinstein
Journal:  Vaccine       Date:  2010-09-28       Impact factor: 3.641

7.  Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.

Authors:  Dylan M Johnson; Jenny D Jokinen; Min Wang; Tia Pfeffer; Irina Tretyakova; Ricardo Carrion; Anthony Griffiths; Peter Pushko; Igor S Lukashevich
Journal:  Vaccine       Date:  2020-02-25       Impact factor: 3.641

Review 8.  Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.

Authors:  Alexander Roberto Precioso; Ricardo Palacios; Beatriz Thomé; Gabriella Mondini; Patrícia Braga; Jorge Kalil
Journal:  Vaccine       Date:  2015-10-14       Impact factor: 3.641

9.  Monoclonal antibody therapy for Junin virus infection.

Authors:  Larry Zeitlin; Joan B Geisbert; Daniel J Deer; Karla A Fenton; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Andrew Hiatt; Michael H Pauly; Jesus Velasco; Kevin J Whaley; Friedrich Altmann; Clemens Gruber; Herta Steinkellner; Anna N Honko; Ana I Kuehne; M Javad Aman; Sara Sahandi; Sven Enterlein; Xiaoguo Zhan; Delia Enria; Thomas W Geisbert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

Review 10.  The complexity and cost of vaccine manufacturing - An overview.

Authors:  Stanley Plotkin; James M Robinson; Gerard Cunningham; Robyn Iqbal; Shannon Larsen
Journal:  Vaccine       Date:  2017-06-21       Impact factor: 3.641

View more
  1 in total

1.  Energy, environmental, economic and social equity (4E) pressures of COVID-19 vaccination mismanagement: A global perspective.

Authors:  Peng Jiang; Jiří Jaromír Klemeš; Yee Van Fan; Xiuju Fu; Raymond R Tan; Siming You; Aoife M Foley
Journal:  Energy (Oxf)       Date:  2021-06-30       Impact factor: 7.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.